Frag 176-191 White Bodybuilding Peptides Powder Fat Loss
Fragment 176-191 Description
Fragment 176-191 is an analog of the growth hor.- mone-releasing factor (GRF) which signals the effects of growth hor.- mone. It is a 15-mer peptide residue of the C-terminus of HGH to which tyrosine is added at the N-terminal end. This synthetically produced hor.- mone is very common to weightlifters and bodybuilders because of a number of physical benefits. Studies claimed that it actually acts on the reduction of excessive adipose tissues such as those in the abdominal area, increase in muscle mass, and enhances the lipid content of the body.
Fragment 176-191 Function
Fragment 176-191 exhibits the ability to burn through stubborn adipose tissue, while increasing energy expenditure, muscle mass, and fat oxidation. All studies have pointed to the fact that the fragment is an effective treatment for obesity and fat loss, and much safer than its Human Growth Hormone counterpart.
Tesamorelin is a stabilized analogue of the g h-releasing factor (GRF) that induces (GH) in a specific and physiological manner. To date, clinical studies suggest that Tesamorelin reduces visceral fat in HIV-infected patients with abdominal lipo-hypertrophy as well as reducing abdominal fat in all individuals studied.
A peptide that increases gh release improved several measures of cognitive function in cognitively normal and mildly impaired older individuals in a placebo-controlled trial, a researcher said here. Scores on standard tests of executive function and verbal memory were significantly higher in participants given tesamorelin (Egrifta), a synthetic analog of gh releasing hormone (GHRH), in a 20-week trial, according to Laura D. Baker, PhD.. Participants taking the drug in the 78-person trial also reported greater subjective improvement in cognition relative to the placebo group.
In animal studies, GHRH administration improved biomarkers of brain function as well as performance on cognition tests. And a 2006 clinical trial with GHRH found small but significant improvements in cognitive test scores in healthy older adults. In the current study, funded by the National Institute on Aging, 41 cognitively normal adults and 37 with mild cognitive impairment were randomized to placebo or tesamorelin at 1 mg/day subcutaneously.
|CJC1294 with DAC||2mg||98%|
|Contact Person :||Miss. Anne|